Qaasid News

Download Our App

Category: 3. Business

  • Flying cars are soaring from pages of science fiction to reality | Driving Into the Future

    Flying cars are soaring from pages of science fiction to reality | Driving Into the Future

    Flying cars are no longer a science fiction fantasy, but are becoming a reality.

    They are currently in production and could be delivered to customers within the next year or two.

    The company is called Alef Aeronautics.

    Founded in 2015, it is at the forefront of the flying car industry, with more than 3,500 pre-orders of its flying cars.

    The Alef Model A Ultralight is a vehicle that can drive and fly, as seen in a testing video where the vehicle elevates and goes airborne over another car.

    The video has over 2 billion views worldwide.

    “A little under a month ago, we started building the first car to be delivered to the actual customer,” said Jim Dukhovny.

    Alef Aeronautics co-founder Jim Dukhovny said his company and technology have two priorities: safety and regulatory compliance.

    Dukhovny said this vehicle will be able to elevate thousands of feet or just 20.

    “At this point at least, the cabin is not pressurized. So you can’t go up to the levels where you need a pressurized cabin,” he said.

    Dukhovny said the current Model A ultralight goes for $300,000.

    But he expects in about a decade, the price will drop to roughly $30,000.

    He called it an EV car first, an aircraft second, with a range of 200 miles on the road and 110 in the air.

    It will fall under existing ultra light aircraft Federal Aviation Administration regulations, which means no certification is required currently.

    “There are rules where you can take off and land. So if you’re imagining a scenario that you’re going to drive on the freeway, take off, fly, and then land on the freeway, that’s not going to happen,” he said.

    He said learning to operate the vehicle will only take a few hours, but also require to learn FAA regulations.

    “So you have to read the sectional map, you have to understand the alpha, bravao airspace and where you can fly, where you cannot fly,” he added.

    The first models are expected to hit the roadways in either Silicon Valley or Hong Kong and will test real world conditions under very controlled testing.

    Copyright © 2026 WPVI-TV. All Rights Reserved.

    Continue Reading

  • US to cut tariffs on Taiwanese goods after investment pledge

    US to cut tariffs on Taiwanese goods after investment pledge

    Natalie Sherman,Business reporterand

    Lily Jamali,North America Technology correspondent

    Bloomberg via Getty Images Employees wearing cleanroom suits walk beneath Automated Material Handling Systems (AMHS) vehicle robots moving along tracks on the ceiling inside the GlobalFoundries semiconductor manufacturing facility in Malta, New York, U.S., on Tuesday, March 16, 2021. Bloomberg via Getty Images

    The US has been pushing to build up its semiconductor industry

    The US said it had agreed to cut the tariffs it charges on goods from Taiwan to 15%, in exchange for hundreds of billions of dollars in investment aimed at boosting domestic production of semiconductors.

    The Commerce Department said the island’s semiconductor and technology enterprises had committed to “new, direct investments” worth at least $250bn (£187bn).

    The deal also provides carve-outs from tariffs for Taiwanese semiconductor companies investing in the US.

    Boosting US production of semiconductor chips, which are found in machines ranging from cars to smart phones, has been a priority for the US since shortages during the Covid-19 pandemic exposed supply chain risks.

    In an interview on CNBC, Commerce Secretary Howard Lutnick said the agreement would help the US become “self-sufficient”.

    “We’re going to bring it all over,” he said.

    The US has devoted hundreds of billions of dollars in government subsidies to the semiconductor industry in recent years, helping to secure and expand investments from the likes of TSMC, the Taiwanese manufacturing giant that dominates the industry.

    As part of its earnings update on Thursday, the company said it was accelerating its investments in the US, where it opened a plant in 2024.

    The factory in Arizona, which now makes chips for Nvidia, Apple, AMD and other major American tech companies, was built with the help of $40bn in US government subsidies passed during the Biden administration.

    Lutnick said the latest trade deal could lead the firm to expand and was also meant to further develop the supply chain, convincing smaller businesses to relocate to the US as well.

    As well as the direct investments from companies, the Taiwanese government will provide $250bn in financing to support firms, according to the Commerce Department.

    Taiwan, a self-governed island claimed by China, had been pushing to reach an agreement with the Trump administration over the duties faced by its exports entering the US, set at 20% last year.

    But it has been wary of demands to transfer its expertise, seen by some as a safeguard against military action.

    The new 15% tariff rate matches the rates the US currently charges on goods from key trade partners such as Japan, South Korea, and the European Union.

    Those rates were agreed in deals stemming from tariffs Trump first announced last April, which he said were aimed at addressing imbalances in trade.

    The Supreme Court is currently weighing a request from businesses and states in the US to strike down those duties, which they claim were imposed in an overreach of presidential power.

    The Trump administration had previously threatened separate, wider tariffs on the semiconductor industry in the name of national security.

    It has so far held off on that proposal, which met with widespread alarm by US firms dependent on imports, including from some firms in the sector.

    The announcement comes as American chip manufacturer Intel, a TSMC rival, has struggled to gain traction making advanced chips designed for artificial intelligence.

    In a surprise move last year, the US government took a 10% stake in Intel but the company is due to cut thousands more American positions in addition to those it has already slashed in recent years.

    Overall, the semiconductor manufacturing sector shed more than 17,000 jobs last year, according to the latest data, despite government efforts to boost the industry.

    Continue Reading

  • Nabors Announces Redemption of 7.500% Senior Guaranteed Notes Due 2028 and Fourth Quarter 2025 Reduction in Net Debt of Approximately $366 Million, Equivalent to $25 per Share

    Nabors Announces Redemption of 7.500% Senior Guaranteed Notes Due 2028 and Fourth Quarter 2025 Reduction in Net Debt of Approximately $366 Million, Equivalent to $25 per Share

    HAMILTON, Bermuda, Jan. 15, 2026 /PRNewswire/ — Nabors Industries Ltd. (“Nabors” or the “Company”) (NYSE: NBR) today announced the full redemption of its outstanding 7.500% Senior Guaranteed Notes due 2028, with a face value of approximately $379 million. The Notes were redeemed at par, plus accrued and unpaid interest, on January 15, 2026.

    Nabors also announced certain preliminary balance sheet figures. As of December 31, 2025, total debt amounted to approximately $2.5 billion. Cash and short-term investments were approximately $940 million. Net debt, defined as total debt less cash and short-term investments, was approximately $1.55 billion as of December 31, 2025, bringing net leverage to its lowest level since 2008. This amount represents a reduction of approximately $366 million – equivalent to approximately $25 per Nabors common share – during the fourth quarter and approximately $550 million since December 31, 2024.  

    Following the redemption, long–term debt stands at approximately $2.15 billion. The Company’s next debt maturity occurs in 2029. Also following the redemption, the weighted average maturity on Nabors’ outstanding debt has increased to 5.3 years, from 3.7 years as of September 30, 2025.

    Anthony G. Petrello, Nabors Chairman, President and CEO, commented, “This redemption represents another meaningful step in advancing our commitment to debt reduction as a core driver of shareholder value. The combination of our opportunistic Parker Wellbore and Quail Tools transactions, together with strong operational execution, contributed to this outcome. We have successfully cleared and extended our financing runway to 2029. These actions materially strengthen our capital structure and position the Company for continued strategic progress.”

    About Nabors Industries

    Nabors Industries (NYSE: NBR) is a leading provider of advanced technology for the energy industry. With presence in more than 20 countries, Nabors has established a global network of people, technology and equipment to deploy solutions that deliver safe, efficient and responsible energy production. By leveraging its core competencies, particularly in drilling, engineering, automation, data science and manufacturing, Nabors aims to innovate the future of energy and enable the transition to a lower-carbon world. Learn more about Nabors and its energy technology leadership: www.nabors.com.

    Forward-looking Statements

    The information included in this press release includes forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. Such forward-looking statements are subject to a number of risks and uncertainties, as disclosed by Nabors from time to time in its filings with the Securities and Exchange Commission. As a result of these factors, Nabors’ actual results may differ materially from those indicated or implied by such forward-looking statements. The forward-looking statements contained in this press release reflect management’s estimates and beliefs as of the date of this press release. Nabors does not undertake to update these forward-looking statements. 

    Non-GAAP Disclaimer

    This press release presents a “non-GAAP” financial measure. The components of this non-GAAP measure are computed by using amounts that are determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Net debt is calculated as total debt minus the sum of cash, cash equivalents and short-term investments.

    This non-GAAP measure has limitations and therefore should not be used in isolation or as a substitute for the amounts reported in accordance with GAAP. However, management evaluates the performance of its operating segments and the consolidated Company based on several criteria, including net debt, because it believes that this financial measure accurately reflects the Company’s liquidity. Securities analysts and investors also use this measure as one of the metrics on which they analyze the Company’s performance. Other companies in this industry may compute this measure differently. A reconciliation of net debt to total debt, which is the nearest comparable GAAP financial measure, is included in the table at the end of this press release.

    Investor Contacts:  William C. Conroy, CFA, Vice President of Corporate Development & Investor Relations, +1 281-775-2423 or via e-mail [email protected], or Kara K. Peak, Director of Corporate Development & Investor Relations, +1 281-775-4954 or via email [email protected]. To request investor materials, contact Nabors’ corporate headquarters in Hamilton, Bermuda at +441-292-1510 or via e-mail [email protected]

    SOURCE Nabors Industries Ltd.

    Continue Reading

  • Casca Named Banking and Financial Services Winner in the 2026 BIG Innovation Awards

    Casca Named Banking and Financial Services Winner in the 2026 BIG Innovation Awards

    CEO and co-founder, Lukas Haffer, was recognized in the Banking and Financial Services category for Innovative Individuals

    SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ — Casca, the first AI-native loan origination platform, is proud to announce that it has been named a Banking and Financial Services Winner in the 2026 BIG Innovation Awards, a global recognition program honoring companies, products, and leaders who are transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.

    “The 2026 BIG Innovation Awards winners show that true innovation is no longer about chasing the latest buzzwords,” said Russ Fordyce, Chief Recognition Officer at the Business Intelligence Group. “It’s about building intelligent platforms, automating workflows with purpose, and making trust, privacy, and resilience the foundation of every breakthrough. These organizations and leaders are not just keeping pace with change, they are shaping the future of global business.”

    Casca was recognized for its outstanding contributions to innovation in banking and financial services. Rather than incrementally improving legacy systems, the company rebuilt one of banking’s slowest and most complex processes from the ground up. Its AI-native loan origination platform replaces outdated lending infrastructure with responsible, automated workflows designed to meet bank-grade underwriting and compliance standards. As a result, community banks and credit unions using Casca are funding small business loans up to 30x faster than industry averages, with end-to-end processing times as short as one to four days.

    “We are honored to receive this recognition, “Casca co-Founder and CEO Lukas Haffer said “This award reflects a belief we’ve held from day one: that responsible, well-designed technology can fundamentally improve access to capital for small businesses while strengthening the role of banks as trusted financial partners. Innovation, to us, means building systems that work in the real world and make a meaningful difference for the people who rely on them.”

    In addition, Lukas Haffer was recognized in the Banking and Financial Services category for Innovative Individuals. Under his leadership, Casca has grown from an early-stage concept into one of the most impactful AI innovations in small business lending. In 2025, Casca raised a $29 million Series A. Casca’s flagship customers – Live Oak Bank, the nation’s leading U.S. Small Business Administration SBA 7(a) lender by dollar volume, Huntington National Bank, the nation’s largest originator, by volume of SBA 7(a) loans, and Bankwell Bank, Casca’s first customer – all invested. 

    Casca joins 159 winners recognized for their contributions to innovation across health, financial services, logistics, manufacturing, and enterprise technology. The 2026 BIG Innovation Awards winners reveal a clear trend: innovation is no longer about just having AI, it’s about how you use it. Winners are building platforms, automating workflows, and focusing on trust, privacy, and security as core to their mission.

    For more information about the BIG Innovation Awards and to view the full list of winners, visit www.bintelligence.com/posts/2026-big-innovation-awards-159-trailblazers-prove-where-innovation-is-really-happening.

    About Casca
    Casca accelerates the loan application and origination process using responsible AI. It is the loan origination platform used by the nation’s leading SBA lenders and FDIC-Insured banks. Founded in 2023 by banking IT experts and AI researchers from Stanford University, Casca is backed by Y Combinator, Canapi Ventures, Peterson Ventures, Clocktower Ventures, The Fintech Fund, and the Sarah Smith Fund. For more information, visit www.cascading.ai and follow us on LinkedIn.

    About Business Intelligence Group
    The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in business. Unlike many recognition programs, these awards are evaluated by business leaders and practitioners who reward programs, products, and people that deliver real, quantifiable excellence rather than marketing narratives.

    SOURCE Cascading AI

    Continue Reading

  • Bosch Rexroth factory workers accept pay deal after strike action

    Bosch Rexroth factory workers accept pay deal after strike action

    Google The grey building has lots dark glass windows. It has a flat roof and an empty car park in the foreground with grass and a tree.Google

    Workers at Bosch Rexroth went on strike in December

    A dispute over jobs, pay and conditions at a hydraulic equipment factory in Glenrothes has been resolved after workers accepted a 4% increase, according the Unite union.

    More than 280 Bosch Rexroth workers have taken the deal, which also includes removing proposed redundancies and plans to change working practices, Unite said.

    It comes after a week of strike action by staff in December, with more workouts planned for Monday.

    The firm’s management said they were pleased the offer had been accepted and that agreed changes would help give the site a sustainable future.

    Unite industrial officer George Ramsay said the employer had “finally listened to its skilled and dedicated workers by removing the threat to slash pay and job security”.

    “The conciliation service Acas also played a valuable role in the resolution of the dispute which must be acknowledged,” he added.

    He said the deal had been secured because of the “determination of our members to stand firm.”

    A spokesman for the Bosch Rexroth Glenrothes management team said: “We are grateful for the positive engagement from employees and their representatives, and we firmly believe that these changes will help to achieve the sustainable future that benefits everyone at the Glenrothes plant.”

    What was the dispute over?

    The union claimed that plans to impose short-time working – when hours are cut if there is not enough work – could see staff lose up to 40% of their take-home pay, equivalent to £1,000 per month.

    It also said the German-owned firm proposed to impose an annualised hours system which “could put workers up to 70 hours in debt.”

    Unite said that, under this system, if a worker is paid for more hours than they have worked, an employer can recover the overpayment on a debt basis.

    Bosch Rexroth had said the proposals aimed to maintain full employment at the Glenrothes site while facing disruptive market conditions.

    He added: “We firmly believe the new proposals are essential to provide the necessary flexibility to respond to market fluctuations.”

    Continue Reading

  • FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC

    FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC

    Squamous NSCLC represents roughly 25–30% of lung cancer cases and, unlike adenocarcinoma, has fewer actionable driver alterations. After progression on frontline chemo-immunotherapy, many patients fall back on single-agent docetaxel, which offers modest benefit and meaningful toxicity—creating a clear unmet need for more effective second-line strategies.

    Non-Small Cell Lung Cancer: Causes, Symptoms, Diagnosis, Treatment Options, and Latest 2025 Advances in Targeted and Immunotherapy

    What Is Gotistobart (BNT316/ONC-392)?

    Gotistobart, also known by its research codes BNT316 or ONC-392, is a next-generation anti–CTLA-4 monoclonal antibody jointly developed by BioNTech SE and OncoC4 in late-stage clinical development across several solid tumor indications, including squamous non–small cell lung cancer (NSCLC) and others.

    Unlike traditional CTLA-4 inhibitors, gotistobart is engineered to be pH-sensitive and to preserve CTLA-4 recycling. When it binds the CTLA-4 receptor on T cells, the antibody-receptor complex is internalized, but under acidic conditions found inside cells, the antibody dissociates rather than triggering lysosomal degradation of CTLA-4. This allows CTLA-4 to return to the cell surface and preserves its function outside the tumor microenvironment, while preferentially depleting immunosuppressive regulatory T cells (Tregs) within the tumor. This tumor-microenvironment-selective action is intended to enhance anti-tumor immunity while potentially limiting peripheral toxicity relative to conventional CTLA-4 blockade.

    Gotistobart is being studied both as monotherapy and in combination with other immunotherapies, and has received regulatory designations—including FDA Fast Track and Orphan Drug status—reflecting its potential in hard-to-treat cancers such as squamous NSCLC.

    Why Orphan Drug Designation matters

    ODD is intended to accelerate development for therapies targeting rare/high-need populations, providing incentives such as tax credits for qualified clinical testing and (if approved) 7 years of marketing exclusivity in the U.S.

    Study Design and Methods

    The ODD announcement is supported by efficacy signals from the ongoing PRESERVE-003 trial (NCT05671510), a global, randomized phase 3 study evaluating gotistobart versus standard chemotherapy in metastatic squamous NSCLC after progression on anti–PD-(L)1 therapy.

    Results

    Phase 3 PRESERVE-003 (dose-confirmation stage; nonpivotal)
    At a median follow-up of 14.5 months, gotistobart monotherapy showed a notable overall survival advantage versus docetaxel:

    • Median OS: not reached (gotistobart) vs 10.0 months (docetaxel)
    • 12-month OS: 63.1% vs 30.3%
    • Risk of death: HR 0.46 (95% CI, 0.25–0.84), P = .0102

    Safety

    In the same dataset, treatment-related toxicity appeared comparable or slightly lower than chemotherapy:

    • Grade ≥3 treatment-related AEs: 42.2% (gotistobart) vs 48.8% (docetaxel)

    Insights

    • If these OS findings hold in the pivotal stage, gotistobart could redefine expectations for post–PD-(L)1, second-line squamous NSCLC, where meaningful OS gains have been difficult to achieve with immunotherapy alone.
    • The therapeutic-index engineering (CTLA-4 recycling concept) is the key scientific bet: maintaining anti-tumor CTLA-4 biology while improving tolerability may be what allows CTLA-4 blockade to succeed as monotherapy in a heavily pretreated population.

    Key Takeaway Messages

    • FDA ODD has been granted to gotistobart for squamous NSCLC.
    • In PRESERVE-003 (dose-confirmation stage), gotistobart showed strong OS separation vs docetaxel (HR 0.46; 12-month OS 63.1% vs 30.3%).
    • Safety appears manageable and at least comparable to chemotherapy in the reported dataset.
    • The program’s differentiator is a pH-sensitive CTLA-4 approach designed around recycling and tumor-selective Treg depletion.

    You Can Watch More on OncoDaily Youtube TV

     

    Continue Reading

  • Stock market today: Live updates

    Stock market today: Live updates

    Traders work on the floor of the New York Stock Exchange (NYSE) in New York City.

    Spencer Platt | Getty Images

    Stocks climbed Thursday, rebounding from back-to-back losses as chip and banks stocks rallied.

    The Dow Jones Industrial Average added 401 points, or 0.8%, boosted by gains in Goldman Sachs and Nvidia. The S&P 500 jumped 0.6%, while the Nasdaq Composite advanced 0.9%.

    Chip plays led the market after Taiwan Semiconductor delivered another record quarter, saying it expects to boost capital spending in 2026 to between $52 billion and $56 billion — an outlook signaling confidence in the artificial intelligence buildout from the world’s largest contract chipmaker. The stock jumped more than 6%. The VanEck Semiconductor ETF (SMH) climbed 3%, with Nvidia and Micron Technology adding more than 2% each.

    “Taiwan Semi’s results today, and more importantly, their capex spending plans point to reassuring investors that the AI trade is not necessarily a bubble at this point,” said Kim Forrest, investment chief at Bokeh Capital Partners. “They’re going to spend money, lots of money, to build out capacity.”

    Bank stocks rose following the latest raft of quarterly earnings. Goldman Sachs advanced 4% after its fourth-quarter profit topped Wall Street estimates. Morgan Stanley jumped nearly 6% after its wealth management unit contributed to top and bottom line beats in the fourth quarter. Both stocks touched fresh 52-week highs.

    A pullback in oil prices was also supportive of the market, with Brent crude oil futures and front-end West Texas Intermediate crude both sliding more than 4%.

    The latest economic data also pointed to a solid jobs market. Jobless claims data for the week ending Jan. 10 came in at 198,000, lower than the 215,000 expected by economists polled by Dow Jones.

    Thursday’s comeback comes on the heels of two straight losing sessions on Wall Street, after a spate of political headlines — concerning heightened risks in Iran and Greenland, and the future of Federal Reserve independence — weighed on investor sentiment.

    Nvidia came under pressure earlier this week after a Reuters report, citing individuals briefed on the matter, said Chinese customs authorities advised customs agents this week that the company’s H200 chips are not allowed to enter the country. The chipmaker has since rebounded.

    Continue Reading

  • Hyatt Newsroom – News Releases

    Unlock Free Nights from Spain to South Beach with the World of Hyatt Credit Card from Chase

    New cardmembers can earn up to five free nights at Category 1-4 Hyatt hotels and resorts with a limited-time offer that transforms everyday spending into bucket-list adventures.

    CHICAGO (January 15, 2026) – The World of Hyatt Credit Card from Chase is offering new cardmembers the chance to earn up to five free nights at Hyatt hotels and resorts around the world. Available January 15 through February 26, 2026, this limited-time offer lets new cardmembers earn:

    • 3 free nights at any participating Category 1-4 Hyatt hotel after spending $5,000 on purchases in the first 3 months of account opening AND

    • 2 additional free nights at any of those hotels after spending $15,000 on purchases in the first 6 months.

    These nights can unlock everything from sun-soaked, beachfront stays at Hyatt Centric San Juan Isla Verde to stylish, city getaways that buzz from check-in to checkout at Hotel Genevieve.

    Choose Your Own 2026 Adventure

    With the opportunity to earn up to 5 free nights through the limited time offer (plus countless more through spending on the card), new cardmembers can shape their year through the experiences that matter most. Whether it’s wandering through storied cities, relaxing poolside, or finding renewal in wide-open spaces, here’s just a glimpse of what those nights could become:

    • The Euro Summer Perfector: Make this year’s Euro Summer itinerary a masterclass in effortless curation. Get a front-row seat to the very best the Mediterranean has to offer by using your free night awards at hotels like Hyatt Centric Malta (Category 2), Hyatt Regency Kotor Bay Resort in Montenegro (Category 4) and Grand Hyatt La Manga Club Golf & Spa in Spain (Category 4).

    • The Live Event Connoisseur: Take your fandom out of the group chat and jet off to some of the world’s most electrifying music and sports capitals. Own the weekend at Hyatt Regency Chicago (Category 4), follow the thrill of the next big game all the way to London with a stay at Hyatt Place London City East (Category 4) or immerse yourself in college football at Hyatt House Lansing / University Area (Category 2). No matter the event, level up your gig-tripping adventures.

    • The Sun-Soaked Mood Re-Setter: Swap your winter blues for beach-soaked stays at Dream South Beach in Florida (Category 4) or immerse yourself in a chic boutique hideaway tucked into Mexico City’s effortlessly cool Condesa neighborhood at Hotel San Fernando (Category 4).

    • The Slow-Travel Seeker: Up your seasonal reset game and slip away for a five-night wellbeing immersion. Check out the sun-drenched tranquility of Grand Hyatt Goa (Category 4), the lush quiet of Alila Ubud (Category 4) or the stylish scene at The Standard, Bangkok Mahanakhon (Category 4).

    These free night awards are valid for one year from issuance.

    The Year of Rewards Awaits

    A new year often comes with the question of which trips are worth planning and how to pay for them. With the World of Hyatt Credit Card, cardmembers can earn points on the purchases they already make, turning everyday moments into more rewarding stays. Even if only planning a single getaway this year, the card can make every swipe work harder for cardmembers, thanks to the accelerator categories. Paired with complimentary elite status and stackable rewards, cardmembers can unlock unforgettable travel experiences faster in 2026.

    In addition to the welcome offer, for every eligible $1 USD spent, cardmembers earn:

    • Up to 9X total points for Hyatt stays (4 Bonus Points per $1 spent on qualifying purchases at Hyatt hotels and resorts, and up to 5 Base Points per eligible $1 spent for being a World of Hyatt member).

    • 2X Bonus Points per every $1 spent on dining; airline tickets purchased directly from the airline, gym memberships, and local transit and commuting.

    • Complimentary World of Hyatt Discoverist status that provides special perks like late checkout (2 p.m.) as available, room upgrades based on availability, and waived resort fees on Free Night Awards.

    • 1X Bonus Point per $1 spent on all other card purchases.

    • A free night award at any Category 1-4 Hyatt hotel or resort each year on your cardmember anniversary.

    Five free nights can take you almost anywhere with World of Hyatt; the only question is where you want to go first? From long-imagined getaways to unplanned adventures, design a year filled with the moments that matter most. To take advantage of this offer, apply for the card by February 26, 2026.

    To learn more, visit chase.com/HyattLTO and start planning your first (or second… or third…) adventure. For more information about Hyatt hotels and resorts, visit Hyatt.com.

    The term “Hyatt” is used in this release for convenience to refer to Hyatt Hotels Corporation and/or one or more of its affiliates.

    Credit Cards are issued by JPMorgan Chase Bank, N.A. Member FDIC. Accounts subject to credit approval. Restrictions and limitations apply. Offer subject to change.

    About Hyatt Hotels Corporation

    Hyatt Hotels Corporation, headquartered in Chicago, is a leading global hospitality company guided by its purpose – to care for people so they can be their best. As of September 30, 2025, the Company’s portfolio included more than 1,450 hotels and all-inclusive properties in 82 countries across six continents. The Company’s offering includes brands in the Luxury Portfolio, including Park Hyatt®, Alila®, Miraval®, Impression by Secrets, and The Unbound Collection by Hyatt®; the Lifestyle Portfolio, including Andaz®, Thompson Hotels®, The Standard®, Dream® Hotels, The StandardX, Breathless Resorts & Spas®, JdV by Hyatt®, Bunkhouse® Hotels, and Me and All Hotels; the Inclusive Collection, including Zoëtry® Wellness & Spa Resorts, Hyatt Ziva®, Hyatt Zilara®, Secrets® Resorts & Spas, Dreams® Resorts & Spas, Hyatt Vivid® Hotels & Resorts, Sunscape® Resorts & Spas, Alua Hotels & Resorts®, and Bahia Principe Hotels & Resorts; the Classics Portfolio, including Grand Hyatt®, Hyatt Regency®, Destination by Hyatt®, Hyatt Centric®, Hyatt Vacation Club®, and Hyatt®; and the Essentials Portfolio, including Caption by Hyatt®, Unscripted by Hyatt, Hyatt Place®, Hyatt House®, Hyatt Studios®, Hyatt Select, and UrCove. Subsidiaries of the Company operate the World of Hyatt® loyalty program, ALG Vacations®, Mr & Mrs Smith, Unlimited Vacation Club®, Amstar® DMC destination management services, and Trisept Solutions® technology services. For more information, please visit www.hyatt.com.

    About World of Hyatt

    World of Hyatt is Hyatt’s award-winning guest loyalty program uniting participating locations in Hyatt’s Luxury Portfolio, including Park Hyatt®, Alila®, Miraval®, Impression by Secrets, and The Unbound Collection by Hyatt®; the Lifestyle Portfolio, including Andaz®, Thompson Hotels®, The Standard®, Dream® Hotels, The StandardX, Breathless Resorts & Spas®, JdV by Hyatt®, Bunkhouse® Hotels, and Me and All Hotels; the Inclusive Collection, including Zoëtry® Wellness & Spa Resorts, Hyatt Ziva®, Hyatt Zilara®, Secrets® Resorts & Spas, Dreams® Resorts & Spas, Hyatt Vivid Hotels & Resorts, Sunscape® Resorts & Spas, and Alua Hotels & Resorts®; the Classics Portfolio, including Grand Hyatt®, Hyatt Regency®, Destination by Hyatt®, Hyatt Centric®, Hyatt Vacation Club®, and Hyatt®; and the Essentials Portfolio, including Caption by Hyatt®, Hyatt Place®, Hyatt House®, Hyatt Studios, and UrCove. Members who book directly through Hyatt channels can enjoy personalized care and access to distinct benefits including Guest of Honor, confirmed suite upgrades at time of booking, diverse wellbeing offerings, digital key, and exclusive member rates. World of Hyatt offers a variety of ways to earn and redeem points for hotel stays, dining and spa services, wellbeing focused experiences through the FIND platform; as well as the benefits of Hyatt’s strategic loyalty collaboration with American Airlines AAdvantage®. Travelers can enroll for free at hyatt.com, download the World of Hyatt app for android and IOS devices and connect with World of Hyatt on Facebook, Instagram, TikTok and X.

    Media Contact:

    Kaitlyn Sheehy

    kaitlyn.sheehy@hyatt.com

    Continue Reading

  • US creates tech alliance to secure AI supply chain, without the EU – Science|Business

    1. US creates tech alliance to secure AI supply chain, without the EU  Science|Business
    2. Qatar and UAE to join U.S.-led effort to bolster technology supply chain  Reuters
    3. Focus on Nvidia Stock (NVDA) as U.S.-Led AI Supply Chain Bloc Expands  TipRanks
    4. Palestinian president leaves hospital in Ramallah – WAFA  Arab News PK
    5. Gulf States Pivot to Power Global AI Infrastructure  Technology Magazine

    Continue Reading

  • SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

    SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

    HIGHLIGHTS

    • Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

    Patient population

    • With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of 67Cu-SAR-bisPSMA each by the data cut-off date.
    • Seven participants received 67Cu-SAR-bisPSMA and two participants were treated with a combination of 67Cu-SAR-bisPSMA with enzalutamide.
    • Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

    Safety

    • The safety profile of 67Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

    Efficacy

    • Six participants had at least two prostate specific antigen (PSA) results following 67Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
    • One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following 67Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

    Next Steps

    • The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

    SYDNEY, Jan. 15, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25th of November 2025 and continue to show promising efficacy and a favourable safety profile of 67Cu-SAR-bisPSMA.

    Lesion uptake of 64Cu-SAR-bisPSMA positron emission tomography (PET) at baseline (left image) and following two cycles of 67Cu-SAR-bisPSMA (8 GBq each; right image). PET image on the right was acquired 1 month after the 2nd cycle. Coloured arrows indicate representative metastatic bone lesions within each region: red – skull; blue – ribs and sternum; orange – spine; green – pelvis. Images shown as maximum intensity projections.

    Lesion uptake of 64Cu-SAR-bisPSMA positron emission tomography (PET) at baseline (left image) and following two cycles of 67Cu-SAR-bisPSMA (8 GBq each; right image). PET image on the right was acquired 1 month after the 2nd cycle. Coloured arrows indicate representative metastatic bone lesions within each region: red – skull; blue – ribs and sternum; orange – spine; green – pelvis. Images shown as maximum intensity projections.

    The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to 67Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of 67Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

    Of the nine participants included in this SRC analysis, six had at least two PSA results following their 67Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

    The safety profile of 67Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to 67Cu-SAR-bisPSMA have been observed to date.

    Trial participant with no detectable disease after 3 cycles of 67Cu-SAR-bisPSMA

    One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of 67Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of 67Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

    The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

    Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer ‘bis’ structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

    “We have already seen a glimpse of the effects of 67Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of 67Cu-SAR-bisPSMA.

    “All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following 67Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

    “Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease.”

    About the SECuRE trial

    The SECuRE trial (NCT04868604)[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using 64Cu/67Cu-SAR-bisPSMA. 64Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent 67Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of 67Cu-SAR-bisPSMA for the treatment of prostate cancer.

    The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of 67Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)[3].

    Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of 67Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

    Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of 67Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company’s Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

    About SAR-bisPSMA

    SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

    67Cu-SAR-bisPSMA and 64Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of 67Cu-SAR-bisPSMA and 64Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

    About Prostate Cancer

    Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease[6].

    About Clarity Pharmaceuticals

    Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

    www.claritypharmaceuticals.com

    For more information, please contact:

    Clarity Pharmaceuticals

    Dr Alan Taylor                                      

    Lisa Sadetskaya

    Executive Chairperson                               

    Director, Corporate Communications

    [email protected]                       

    [email protected]

    References

    1. Clarity Pharmaceuticals. SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences. https://www.claritypharmaceuticals.com/news/secure-update/
    2. ClinicalTrials.gov Identifier: NCT04868604, https://clinicaltrials.gov/ct2/show/NCT04868604
    3. Clarity Pharmaceuticals. SECuRE trial update: First patient treated in the Phase II Cohort Expansion. https://www.claritypharmaceuticals.com/news/secure-fp-phase2/
    4. Emmett L et al. ENZA-p Trial Investigators; Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025 Mar;26(3):291-299. doi: 10.1016/S1470-2045(25)00009-9.
    5. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834
    6. American Cancer Society: Key Statistics for Prostate Cancer. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

    This announcement has been authorised for release by the Executive Chairperson.

    SOURCE Clarity Pharmaceuticals

    Continue Reading